Lai Jenn-Haung
Rheumatology/Immunology and Allergy, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, China.
Acta Pharmacol Sin. 2002 Dec;23(12):1093-101.
Autoimmune diseases characterized by activation of immune effector cells and damage of target organs are currently treated with a combination of several disease-modifying antirheumatic drugs (DMARDs) that preserve different immunomodulatory mechanisms. Such a combination treatment strategy not only provides synergistic effects but also reduces side effects from individual drug. Tetrandrine (Tet), purified from a creeper Stephania tetrandra S Moore, is a bis-benzylisoquinoline alkaloid and has been used to treat patients with silicosis, autoimmune disorders, and hypertension in Mainland China for decades. The accumulated studies both in vitro and in vivo reveal that Tet preserves a wide variety of immunosuppressive effects. Importantly, the Tet-mediated immunosuppressive mechanisms are evidently different from some known DMARDs. The synergistic effects have also been demonstrated between Tet and other DMARDs like FK506 and cyclosporin. These results highlight Tet a very potential candidate to be considered as one of DMARDs in the treatment of autoimmune diseases, especially rheumatoid arthritis. This review summarizes evidence-based in vivo and in vitro studies on this potential Chinese immunosuppressive herb.
以免疫效应细胞激活和靶器官损伤为特征的自身免疫性疾病,目前采用多种改善病情抗风湿药(DMARDs)联合治疗,这些药物具有不同的免疫调节机制。这种联合治疗策略不仅能提供协同效应,还能减少单一药物的副作用。粉防己碱(Tet)从防己科植物粉防己中提取,是一种双苄基异喹啉生物碱,在中国大陆已用于治疗矽肺、自身免疫性疾病和高血压患者数十年。大量的体外和体内研究表明,粉防己碱具有多种免疫抑制作用。重要的是,粉防己碱介导的免疫抑制机制明显不同于一些已知的DMARDs。粉防己碱与其他DMARDs如FK506和环孢素之间也已证明具有协同效应。这些结果突出表明粉防己碱是治疗自身免疫性疾病,尤其是类风湿性关节炎时,非常有潜力被视为DMARDs之一的候选药物。本综述总结了关于这种具有潜在免疫抑制作用的中国草药的体内和体外循证研究。